Sonoo Advani, MD
Endocrinology, Diabetes & Metabolism · West Orange, NJNPI 1982669123
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,338 of the $34,203 with a category attached, or 68.2%. Boehringer Ingelheim accounts for 61.7% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $14,508 and has fallen 95.7% since, to $621 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $104.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$21K
- Lilly USA, LLC$9K
- Amgen$885
- Novo Nordisk$850
- Dexcom, Inc.$440
- Sanofi-aventis U.S. LLC$190
- plus $1K from 26 others
What the payments were for
- Consulting fees$2,9259%
- Speaking & faculty fees$23,33868%
- Travel & lodging$2,1816%
- Food & beverage$5,55616%
- Education$2031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 54 | $21,103 |
| Lilly USA, LLC | 53 | $9,456 |
| Amgen(2 entities) | 31 | $885 |
| Novo Nordisk | 77 | $850 |
| Dexcom, Inc. | 23 | $440 |
| Sanofi-aventis U.S. LLC | 19 | $190 |
| Medtronic(2 entities) | 7 | $138 |
| Amneal Pharmaceuticals LLC | 8 | $122 |
| Esperion Therapeutics, Inc. | 1 | $116 |
| Abbott | 4 | $85 |
| AbbVie | 6 | $84 |
| Tandem Diabetes Care, Inc. | 4 | $79 |
| Insulet Corporation | 4 | $73 |
| Alvogen Inc | 4 | $67 |
| Azurity Pharmaceuticals, Inc. | 3 | $52 |
| Acella Pharmaceuticals, LLC | 3 | $48 |
| Neurocrine Biosciences, Inc. | 3 | $47 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 1 | $34 |
| Zealand Pharma US, Inc. | 2 | $34 |
| Radius Health, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| BETA Bionics, Inc. | 1 | $27 |
| AstraZeneca | 2 | $26 |
| IBSA Pharma Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
| BD | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,203 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $172,918 |
| MounjaroTirzepatide | 99 | $158,749 |
| JardianceEmpagliflozin | 118 | $154,523 |
| TrulicityDulaglutide | 63 | $112,057 |
| FarxigaDapagliflozin Propanediol | 64 | $75,594 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $33,403 |
| Teriparatide | 12 | $28,119 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $19,923 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $19,482 |
| Armour ThyroidThyroid,pork | 66 | $7,029 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $6,560 |
| Levothyroxine Sodium | 498 | $6,554 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $5,462 |
| Novolog FlexpenInsulin Aspart | 21 | $5,188 |
| SynthroidLevothyroxine Sodium | 73 | $4,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $9,456 | $270,806162 claims |
| Novo NordiskOzempic | $850 | $172,91891 claims |
| Boehringer IngelheimJardiance | $21,103 | $154,523118 claims |
| AstraZenecaFarxiga | $26 | $75,59464 claims |
| Alvogen IncTeriparatide | $67 | $28,11912 claims |
| AbbVieArmour Thyroid, Synthroid | $84 | $11,786139 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $122 | $8,109513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in West Orange
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.